Characteristic | Value |
---|---|
Age (years), median (IQR) | 52.6 (46.3–60.2) |
Sex, n (%) | |
Male | 39 (75) |
Female | 13 (25) |
Diagnosis, n (%) | |
Nasopharyngeal cancer | 44 (84.6) |
Oropharyngeal cancer | 8 (15.4) |
Clinical T classification, n (%) | |
T1 | 6 (11.5) |
T2 | 14 (26.9) |
T3 | 12 (23.1) |
T4 | 20 (38.5) |
Clinical N classification, n (%) | |
N0 | 1 (1.9) |
N1 | 9 (17.3) |
N2 | 30 (57.7) |
N3 | 12 (23.1) |
Prescribed radiotherapy dose (Gy), median (IQR) | 72 (70–74) |
Pretreatment thyroid volume (cm3), mean (SD) | 15.4 (6.5) |
Thyroid dose (Gy), median (IQR) | 44.1 (37.4–50.4) |
Pituitary dose (Gy), median (IQR) | 50.3 (23.6–65.1) |
Time from end of radiotherapy to PET (days), median (IQR) | 93 (77–112) |
RIHT, n (%) | |
Yes | 20 (42) |
No | 30 (58) |
Time from end of radiotherapy to RIHT (months), median (IQR) | 22.7 (16.4–25.2) |